Bayer, BioNxt Solutions, Evotec – Artificial intelligence as a gamechanger in pharmaceutical research

Bayer – Between risks and pipeline potential

Bayer's pharmaceuticals division, which has an annual turnover of around EUR 18 billion, is proving robust despite the expiration of patent protection for the blood thinner Xarelto. Growth drivers such as the kidney medicine Kerendia and the prostate cancer drug Nubeqa, which saw double-digit growth, offset the risks posed by generic competition. The promising late-stage pipeline, including the upcoming 2025 market launches of Elinzanetant (for menopause symptoms) and Acorimidis (for heart failure), strengthens confidence in stable revenues. CEO Bill Anderson's "Dynamic Shared Ownership" model aims to cut costs by EUR 2 billion through job cuts and streamlined processes. The 4% quarterly growth highlights the strength of the segment.

The Crop Science division continues to struggle with glyphosate lawsuits. However, payments have fallen significantly since the record year of 2020 (EUR 13.3 billion). At the same time, Bayer is driving innovation with products such as the "Preceon Smart Corn System," which enables more precise seed planting. With 13 projects in the Crop Protection pipeline and digital agricultural solutions, the Company aims to secure its position. However, the market values the segment below average, although new products could generate leaps in revenue from 2026. The long-term valuation opportunity lies in ignoring the legal risks that are already priced in.

Bayer is prioritizing debt reduction from around EUR 35 billion and cutting the dividend from EUR 2.40 to EUR 0.11. The price-earnings ratio (P/E) of 5.5 seems favorable, especially in comparison to BASF at 7.1 or Johnson & Johnson at 12. Although glyphosate risks and pharmaceutical margins are a burden, the focus on highly profitable consumer health products and pipeline successes could turn the tide. A key factor will be whether the debt ratio falls and Bayer can re-enter M&A for early-stage pharmaceutical projects. The current price of EUR 22.73 reflects the fact that there are still some uncertainties that need to be resolved.

BioNxt Solutions – Breakthrough potential in key markets

BioNxt Solutions is setting new standards with its latest strategic decision. The planned move to the state-of-the-art Gen-Plus Contract Research and Development Organization in Munich starting in March 2025 underlines the Company's drive for innovation. The facility not only enables accelerated development cycles for active ingredients such as Cladribine but also strengthens European networking through collaborations with leading biotech partners. At the same time, new patents in the US, Europe, and Japan secure the unique position of sublingual therapies for multiple sclerosis – a strategic move in the billion-dollar market for neurological diseases.

BioNxt combines medical progress with a clever market strategy. The flagship project BNT23001, a sublingual thin-film formulation of the active ingredient cladribine for MS patients, could start the clinical bioequivalence study as early as Q1 2025 with its high bioequivalence to conventional therapies. This study takes less than 30 days and, if completed successfully, could be a milestone for the Company. At the same time, the result serves as proof of concept for both the main product and the film-coating products under development for autoimmune diseases.

At the same time, the Company plans, according to a statement from February 19, to tap into the booming anti-aging sector (market value of USD 93 billion by 2027) with sublingual products to slow down the aging process within 90 days. To do this, the Company is focusing on sublingual and oral products with active ingredients that have shown promising results in extending fertility and promoting healthier aging. This dual strategy combines short-term pipeline advancements with long-term growth opportunities – an attractive scenario for investors looking for transformative healthcare solutions. The stock, which had been on an upward trend since December, has recently consolidated and is currently trading at EUR 0.30.

Evotec - Growth drivers vs. structural challenges

Evotec, once a model company in the drug development industry, has been showing the first signs of recovery since the fall of 2024 due to takeover rumors. But appearances are deceiving. Despite revenue growth projected to reach an estimated EUR 800 million in 2024, the balance sheet is suffering. Profit slipped from around EUR 215 million in 2021 to an estimated EUR -144 million in 2024. In addition, the takeover by Halozyme failed, whose share price rose by 10% after the withdrawal. Nevertheless, CEO Christian Wojczewski emphasizes: "Evotec remains a global market leader in early-stage research."

The Hamburg-based company focuses on future technologies: artificial intelligence for drug prediction, a unique patient database, and partnerships with pharmaceutical giants such as Bristol Myers Squibb. Most recently, Evotec secured USD 4.5 million in funding from South Korea for lung disease research. Discovery revenues rose by 60%, and cost savings are on track. But the market remains skeptical. Competitors such as Lonza and Genmab are entering the lucrative CRO sector, while Evotec is revising its organizational structure – including job cuts and a focus on core technologies such as cell therapy. "We no longer run a start-up but a billion-dollar company," says Wojczewski.

Financially, Evotec is stable with liquidity of EUR 75 million, revolving credit lines of EUR 250 million, and moderate debt of around EUR 115 million. The price-to-book ratio is just over 1.0. Analyst targets range from EUR 4 to EUR 22. The key lies in the turnaround in profitability starting in 2026 – when the free cash flow is expected to turn positive. Until then, the share remains a speculative game for the patient: Those who believe in the power of partnerships, AI expertise, and the outsourcing trend in the pharmaceutical industry could be rewarded in the long term. The share price is moving sideways and currently stands at EUR 8.24.

Bayer relies on a strong pipeline and cost reductions to remain profitable despite patent expiries and legal risks. BioNxt Solutions scores with innovative sublingual therapies and a new research site in Munich to accelerate development and access new markets. Evotec, on the other hand, is struggling with structural challenges but is relying on AI and partnerships to secure long-term growth. All three companies show that innovation and strategic decisions are crucial to remaining successful in a rapidly changing market environment – clear proof of the industry's dynamism in 2025.